When observing Rigel Pharmaceuticals and Amicus Therapeutics, we can see that both biotech companies are dedicated to developing and commercializing treatment solutions for rare medical conditions, aiming to establish a leading position in their respective fields. Rigel focuses on drug development in immunology, oncology, and rare diseases, while Amicus concentrates on rare and genetic diseases, particularly the treatment of lysosomal storage disorders.

In-depth understanding of the fundamentals of these two companies reveals that Rigel's top drug, Tavalisse, generated approximately $68.5 million in revenue in the first half of 2025, with a year-on-year growth rate of 44%. This oral medication is primarily used to treat adult patients with chronic immune thrombocytopenic purpura (ITP), and its sales momentum is expected to remain strong in the second half of 2025. At the same time, the company also has a second FDA-approved drug, Rezlidhia, used to treat relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation, which saw a year-on-year sales increase of 31% in the first half of 2025. Additionally, after Rigel acquired the commercial rights to Gavreto in 2024, this drug also demonstrated impressive performance in driving revenue growth for the company.

In addition, Rigel is expanding its market influence and enhancing its marketing infrastructure to ensure stable sales growth. The company's total revenue is expected to reach a range of $270 million to $280 million by 2025, which is an increase from the previous estimate of $200 million to $210 million. The company is also developing a new IRA dual inhibitor, R289, aimed at treating patients with low-risk myelodysplastic syndromes (MDS).

For Amicus, Galafold has performed steadily since its launch, with sales reaching approximately $233 million in the first half of 2025, driven by label expansion and approvals in more regions. The drug has strong intellectual property protection in the United States. The company's other combination therapy, Pombiliti + Opfolda, is primarily used for the treatment of adult late-onset Pompe disease (LOPD), and it has also received approval in Europe. In the first half of 2025, Pombiliti + Opfolda sales were $46.8 million, a year-on-year increase of 74%.

Although Amicus has gained a certain market share through Pombiliti + Opfolda, the company remains highly dependent on Galafold for its overall revenue, making it more vulnerable to potential regulatory challenges. Furthermore, despite the steady launch of Pombiliti + Opfolda, it has not yet resulted in significant incremental sales.

Regarding future expectations, Rigel is widely optimistic, with its sales and earnings per share expected to grow by approximately 57% and 415% respectively by 2025. In contrast, Amicus has more modest growth expectations, with sales and earnings per share projected to increase by only about 18% and 29%.

In terms of price performance, Rigel's stock price has increased by 80.1% to date, while Amicus has decreased by 11.3%. In terms of valuation, Amicus appears to be more expensive, with a higher price-to-sales ratio than Rigel.

In summary, Rigel's current strong growth momentum, positive financial guidance, and relatively low valuation give it an advantage compared to Amicus. Although Amicus has made progress in diversifying its growth, its excessive reliance on Galafold and competitive pressures in the industry remain risks that cannot be ignored. Analysts believe that Rigel's future sales and earnings per share will continue to grow significantly, which bodes well for its opportunities.🎯